Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment
Acta Haematologica · 2025
DOI: 10.1159/000545709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, 2025. Verfasst von Jingyi Bi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, C…. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Hydroxamic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
We conducted a single-arm, open-label dose-exploration study to evaluate the safety and efficacy of the histone deacetylase inhibitor tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone (C-PDD) in treating relapsed and refractory multiple myeloma (RRMM) patients.
Methods
Eighteen patients were enrolled from August 2020 to May 2021, receiving 21-day cycles of C-PDD.
Results
Eighteen cases were analyzed, with a median prior treatment line of 2 (range: 1-4). The median number of completed treatment cycles was 4 (range: 1-8). The overall response rate was 57%, including 14% complete response, 14% very good partial response, and 29% partial response. Both bortezomib-sensitive and refractory groups had a response rate of 57%. The response rate was 100% in patients with extramedullary extraosseous involvement. The median follow-up was 42 months (range: 3-44), with median progression-free survival of 7 months and median overall survival of 24.5 months. Grade 3-4 hematologic adverse events included thrombocytopenia (50%), neutropenia (33%), and anemia (33%). Non-hematologic adverse events were mostly grade 1-2, with one case of grade 3 peripheral sensory neuropathy.
Conclusion
The C-PDD regimen showed efficacy in RRMM, including bortezomib-refractory disease and EME patients. The optimal dose and combination need to be explored in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.
- Peking University College of Chemitry and Molecular Engineering, Beijing, China.
- Fuxing Hospital, Capital Medical University, Beijing, China.
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China, 5290675@qq.com.
- Hematology Department, Peking University Shougang Hospital, Beijing, China, 5290675@qq.com.
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China, lujin@pku.edu.cn.
Zitieren
APA
Bi, J., Dou, X., Liang, R., Wen, L., Liu, Y., Lei, X., Wang, L., Guo, H., Huang, X., Wang, M., & Lu, J. (2025). Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment. Acta Haematologica. https://doi.org/10.1159/000545709
Vancouver
Bi J, Dou X, Liang R, Wen L, Liu Y, Lei X, et al. Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment. Acta Haematologica. 2025. doi:10.1159/000545709
BibTeX
@article{Bi2025,
author = {Bi, Jingyi and Dou, Xuelin and Liang, Ruqi and Wen, Lei and Liu, Yang and Lei, Xiaoguang and Wang, Liru and Guo, Huixia and Huang, Xiaojun and Wang, Mingdi and Lu, Jin},
title = {Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment},
journal = {Acta Haematologica},
year = {2025},
doi = {10.1159/000545709}
}
EUVIMED